Skip to main content
. 2021 Jun 19;14(6):2184–2192. doi: 10.1111/cts.13075

FIGURE 1.

FIGURE 1

Association between FCGR3A SNP rs396991 and clinical response to infliximab in 76 pediatric patients with inflammatory bowel disease at the end of induction (14 weeks of therapy) or during maintenance (at 22 and 52 weeks of therapy). Logistic regression was used for statistical analysis